Consensus Gilead Sciences, Inc.

Equities

GILD

US3755581036

Delayed Nasdaq Other stock markets 04:00:00 2023-10-02 pm EDT			5-day change	1st Jan Change
74.10 ^USD	-1.12%		-0.98%	-13.69%

Sep. 28	GSK lifts growth ambitions for HIV business on long-acting drug	RE
Sep. 19	Gilead Sciences Gets EU Committee's Positive Opinion on Expanding Veklury's Indication	MT

Evolution of the average Target Price on Gilead Sciences, Inc.

Price target over the last 5 years

History : Analyst Recommendations

6161e0041e1ae848b25de3d821cc9.fOTYg07zkd8o7uqDFIaGOixkDWu23cqiLHFGheSsb70.TtePyBSiqYl_nKmwV9zBa0EpXTiB747GYT0v9andKYgOvIfBNLmom36IiQ~08c9243633df637b16bf82e1fcd68547

Analyst Recommendations on Gilead Sciences, Inc.

BofA Securities Upgrades Gilead Sciences to Buy From Neutral, Adjusts Price Target to $95 From $88	Sep. 08	MT
HSBC Initiates Gilead Sciences With Reduce Rating, Price Target is $71	Sep. 06	MT
ANALYST RECOMMENDATIONS : Amgen, Biogen, Broadcom, Fedex, Salesforce...	Sep. 06
UBS Adjusts Gilead Sciences Price Target to $84 From $88, Maintains Neutral Rating	Aug. 08	MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $85 From $84, Maintains Neutral Rating	Aug. 04	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $88 From $86, Maintains Equal-Weight Rating	Aug. 04	MT
RBC Lifts Price Target on Gilead Sciences to $84 From $83, Maintains Sector Perform Rating	Aug. 04	MT
Piper Sandler Lowers Gilead Sciences' Price Target to $100 From $105, Overweight Rating Kept	Jul. 24	MT
Barclays Adjusts Gilead Sciences' Price Target to $80 From $81, Keeps Equalweight Rating	Jul. 24	MT
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $80 From $85, Maintains Neutral Rating	Jul. 20	MT
Barclays Adjusts Price Target on Gilead Sciences to $81 From $84, Maintains Equalweight Rating	Jul. 11	MT
RBC Lowers Gilead Sciences' Price Target to $83 From $88, Keeps Sector Perform Rating	Jul. 07	MT
BMO Capital Upgrades Gilead Sciences to Outperform From Market Perform, Adjusts Price Target to $100 From $90	May. 16	MT
ANALYST RECOMMENDATIONS : Amazon, Amdocs, Gilead, MacFarlane, TUI...	May. 16
UBS Adjusts Gilead Sciences Price Target to $88 From $91, Maintains Neutral Rating	May. 02	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $86 From $85, Maintains Equal-Weight Rating	May. 01	MT
Piper Sandler Assumes Gilead Sciences at Overweight With $105 Price Target	Apr. 28	MT
RBC Capital Adjusts Price Target on Gilead Sciences to $88 From $87, Maintains Sector Perform Rating	Apr. 28	MT
ANALYST RECOMMENDATIONS : Antofagasta, Capricorn Energy, Gilead, Intel, Old Dominion...	Apr. 28
UBS Adjusts Gilead Sciences Price Target to $91 From $90, Maintains Neutral Rating	Apr. 21	MT
Morgan Stanley Raises Price Target on Gilead Sciences to $85 From $81, Maintains Equalweight Rating	Apr. 12	MT
RBC Capital Adjusts Gilead Sciences Price Target to $87 From $86, Maintains Sector Perform Rating	Apr. 06	MT
RBC Trims Price Target on Gilead Sciences to $86 From $87, Maintains Sector Perform Rating	Mar. 06	MT
Mizuho Securities Adjusts Gilead Sciences Price Target to $101 From $88, Maintains Buy Rating	Feb. 14	MT
UBS Adjusts Gilead Sciences Price Target to $90 From $85, Maintains Neutral Rating	Feb. 07	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

74.10USD

Average target price

91.36USD

Spread / Average Target

+23.30%

High Price Target

116.00USD

Spread / Highest target

+56.55%

Low Price Target

71.00USD

Spread / Lowest Target

-4.18%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gilead Sciences, Inc.

BofA Securities
HSBC
UBS
Goldman Sachs
Morgan Stanley
RBC Capital Markets
Piper Sandler
Barclays
Cantor Fitzgerald
BMO Capital
Mizuho Securities
SVB Securities LLC
Wells Fargo Securities
Oppenheimer
Cowen
Maxim
Truist Securities
JPMorgan Chase
Argus
SVB Leerink
Credit Suisse
Bernstein
Redburn
DZ BANK	Elmar Kraus

Ratings for Gilead Sciences, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar